C4X Discovery Holdings Inkomsten in het verleden
Verleden criteriumcontroles 3/6
C4X Discovery Holdings has been growing earnings at an average annual rate of 16%, while the Life Sciences industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 47.1% per year. C4X Discovery Holdings's return on equity is 42.9%, and it has net margins of 42.8%.
Belangrijke informatie
16.0%
Groei van de winst
44.8%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 36.9% |
| Inkomstengroei | 47.1% |
| Rendement op eigen vermogen | 42.9% |
| Nettomarge | 42.8% |
| Laatste winstupdate | 31 Jan 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why We're Watching C4X Discovery Holdings' (LON:C4XD) Cash Burn Situation
Feb 07
Companies Like C4X Discovery Holdings (LON:C4XD) Are In A Position To Invest In Growth
Jul 05We're Not Very Worried About C4X Discovery Holdings' (LON:C4XD) Cash Burn Rate
Oct 07Companies Like C4X Discovery Holdings (LON:C4XD) Are In A Position To Invest In Growth
Mar 27We Think C4X Discovery Holdings (LON:C4XD) Can Afford To Drive Business Growth
Dec 12Opbrengsten en kosten
Hoe C4X Discovery Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Jan 24 | 25 | 11 | 4 | 11 |
| 31 Oct 23 | 13 | 0 | 4 | 11 |
| 31 Jul 23 | 2 | -11 | 4 | 11 |
| 30 Apr 23 | 3 | -9 | 4 | 11 |
| 31 Jan 23 | 4 | -8 | 4 | 11 |
| 31 Oct 22 | 4 | -8 | 4 | 10 |
| 31 Jul 22 | 3 | -8 | 4 | 9 |
| 30 Apr 22 | 4 | -6 | 4 | 9 |
| 31 Jan 22 | 6 | -5 | 4 | 9 |
| 31 Oct 21 | 6 | -4 | 3 | 9 |
| 31 Jul 21 | 6 | -4 | 3 | 8 |
| 30 Apr 21 | 3 | -6 | 3 | 7 |
| 31 Jan 21 | 0 | -7 | 3 | 7 |
| 31 Oct 20 | 0 | -8 | 3 | 7 |
| 31 Jul 20 | 0 | -8 | 3 | 7 |
| 30 Apr 20 | 0 | -9 | 3 | 8 |
| 31 Jan 20 | 0 | -10 | 3 | 9 |
| 31 Oct 19 | 0 | -10 | 3 | 10 |
| 31 Jul 19 | 0 | -11 | 3 | 11 |
| 30 Apr 19 | 4 | -7 | 3 | 10 |
| 31 Jan 19 | 7 | -3 | 3 | 9 |
| 31 Oct 18 | 7 | -2 | 3 | 8 |
| 31 Jul 18 | 7 | -1 | 3 | 7 |
| 30 Apr 18 | 4 | -4 | 3 | 7 |
| 31 Jan 18 | 0 | -7 | 3 | 6 |
| 31 Oct 17 | 0 | -7 | 3 | 6 |
| 31 Jul 17 | 0 | -7 | 3 | 6 |
| 30 Apr 17 | 0 | -6 | 2 | 6 |
| 31 Jan 17 | 0 | -6 | 2 | 6 |
| 31 Oct 16 | 0 | -5 | 2 | 5 |
| 31 Jul 16 | 0 | -5 | 2 | 5 |
| 30 Apr 16 | 0 | -5 | 2 | 5 |
| 31 Jan 16 | 0 | -5 | 1 | 5 |
| 31 Oct 15 | 0 | -4 | 1 | 4 |
| 31 Jul 15 | 0 | -3 | 1 | 3 |
| 30 Apr 15 | 0 | -2 | 1 | 2 |
| 31 Jan 15 | 0 | -2 | 1 | 2 |
| 31 Oct 14 | 0 | -1 | 1 | 1 |
| 31 Jul 14 | 1 | -1 | 1 | 1 |
| 31 Jul 13 | 1 | 0 | 1 | 0 |
Kwaliteitswinsten: C4XD has a high level of non-cash earnings.
Groeiende winstmarge: C4XD became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: C4XD has become profitable over the past 5 years, growing earnings by 16% per year.
Versnelling van de groei: C4XD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: C4XD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Rendement op eigen vermogen
Hoge ROE: C4XD's Return on Equity (42.9%) is considered outstanding.